X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES STERLING BIOTECH ALKEM LABORATORIES/
STERLING BIOTECH
 
P/E (TTM) x - -1.7 - View Chart
P/BV x 7.4 0.1 11,472.7% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALKEM LABORATORIES   STERLING BIOTECH
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
STERLING BIOTECH
Dec-13
ALKEM LABORATORIES/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,58911 15,133.3%   
Low Rs1,2323 36,235.3%   
Sales per share (Unadj.) Rs417.526.8 1,557.3%  
Earnings per share (Unadj.) Rs56.3-15.0 -376.4%  
Cash flow per share (Unadj.) Rs64.7-5.5 -1,184.5%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.954.9 533.8%  
Shares outstanding (eoy) m119.57267.87 44.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,303.2%   
Avg P/E ratio x25.1-0.5 -5,392.1%  
P/CF ratio (eoy) x21.8-1.3 -1,713.4%  
Price / Book Value ratio x4.80.1 3,802.3%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6531,862 9,059.1%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m9,171547 1,677.3%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m49,9157,181 695.1%  
Other income Rs m1,64543 3,861.7%   
Total revenues Rs m51,5617,223 713.8%   
Gross profit Rs m8,482947 895.8%  
Depreciation Rs m1,0062,543 39.5%   
Interest Rs m6714,377 15.3%   
Profit before tax Rs m8,451-5,931 -142.5%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606-1,924 -83.5%   
Profit after tax Rs m6,731-4,007 -168.0%  
Gross profit margin %17.013.2 128.9%  
Effective tax rate %19.032.4 58.6%   
Net profit margin %13.5-55.8 -24.2%  
BALANCE SHEET DATA
Current assets Rs m27,06214,335 188.8%   
Current liabilities Rs m15,32449,809 30.8%   
Net working cap to sales %23.5-494.0 -4.8%  
Current ratio x1.80.3 613.6%  
Inventory Days Days67403 16.5%  
Debtors Days Days41171 24.2%  
Net fixed assets Rs m12,61055,432 22.7%   
Share capital Rs m239268 89.2%   
"Free" reserves Rs m34,49013,935 247.5%   
Net worth Rs m35,02714,701 238.3%   
Long term debt Rs m1,2129,478 12.8%   
Total assets Rs m54,38773,988 73.5%  
Interest coverage x13.6-0.4 -3,832.0%   
Debt to equity ratio x00.6 5.4%  
Sales to assets ratio x0.90.1 945.7%   
Return on assets %13.60.5 2,717.1%  
Return on equity %19.2-27.3 -70.5%  
Return on capital %24.9-6.4 -386.8%  
Exports to sales %12.925.9 50.0%   
Imports to sales %3.10.2 1,816.3%   
Exports (fob) Rs m6,4611,860 347.4%   
Imports (cif) Rs m1,54012 12,625.4%   
Fx inflow Rs m6,5631,860 352.9%   
Fx outflow Rs m3,01225 12,100.0%   
Net fx Rs m3,5521,835 193.6%   
CASH FLOW
From Operations Rs m7,2591,719 422.3%  
From Investments Rs m1,864-3,148 -59.2%  
From Financial Activity Rs m-9,2731,426 -650.3%  
Net Cashflow Rs m-150-3 4,411.8%  

Share Holding

Indian Promoters % 66.9 33.9 197.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.0 -  
FIIs % 0.0 9.9 -  
ADR/GDR % 0.0 16.9 -  
Free float % 0.0 39.3 -  
Shareholders   68,381 21,482 318.3%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS